Acute inflammatory conditions

Influenza
#Acute inflammatory conditions #Biopharmaceuticals #Human trials #Immunomodulators #Infectious diseases #Influenza

New results for severe influenza and inflammatory conditions 

Poolbeg Pharma, an infectious disease-focused biopharmaceutical company, has announced data from the bacterial lipopolysaccharide (‘LPS’) human challenge trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need arising from severe influenza and other acute inflammatory conditions.   POLB 001… Read More

#News